TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of ...

A blending of committed youth groups from Fayette County gathered at the Summit Bechtel Reserve last weekend for a special Fayette Prevention Coalition collaboration.

Preview this article 1 min If the company moves forward with the project on a 186-acre site, it could entail more than $1 billion in investment in a growing area of Fort Worth. Get the latest in this ...

While the company hasn't confirmed its plans, public documents indicate more than 1,400 jobs could be created and tens of millions of dollars could be invested.

The unified JavaScript runtime standard is an idea whose time has come. Here’s an inside look at the movement for server-side JavaScript interoperability.

Abstract: Faculty websites are often the first entry point for students seeking research opportunities, yet they vary widely in showing inclusive values. We examine how biology faculty websites at ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee ...

Twelve-month data from the VOLT-AF Global IDE study found that the Volt PFA System had an industry-leading success rate (84.2%) of freedom from documented rhythm recurrence among all competitive PFA ...

JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the presentation of four ...

Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority Review Preliminary data from Phase ...

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at ...